Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAssetmark, Inc
Latest Disclosed Ownership14,207 shares
Latest Disclosed Value $ 4,700,557
Assetmark, Inc reports 11.39% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 6, 2026 - Assetmark, Inc filed a 13F-HR form disclosing ownership of 14,207 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $4,058,940 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 23, 2026 disclosing 16,033 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -11.39% during the quarter. The current value of the position is $3,577,323 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,207 -1,826 -11.39 4,701 -26.27 0.0096
2026-01-23 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,033 4,115 34.53 6,375 17.32 0.0130
2025-11-06 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,918 375 3.25 5,435 44.41 0.0116
2025-08-04 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,543 902 8.48 3,764 30.98 0.0089
2025-05-06 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,641 608 6.06 2,873 21.74 0.0079
2025-02-06 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,033 847 9.22 2,361 -6.57 0.0064
2024-11-01 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,186 700 8.25 2,526 22.56 0.0072
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,486 905 11.94 2,062 82.07 0.0064
2024-05-07 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,581 668 9.66 1,133 -14.44 0.0037
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,913 1,135 19.64 1,323 29.33 0.0048
2023-10-27 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,778 934 19.28 1,023 11.20 0.0041
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 4,844 475 10.87 920 5.14 0.0036
2023-05-05 2023-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 4,369 306 7.53 875 -9.33 0.0036
2023-02-10 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,063 1,271 45.52 966 72.63 0.0042
2022-11-01 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,792 2,792 559 0.0026
2020-05-12 2020-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 0 -96 -100.00 0 -100.00
2020-02-11 2019-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 96 0 0.00 11 37.50 0.0001
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 96 0 0.00 8 14.29 0.0001
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 96 -45 -31.91 7 -46.15 0.0001
2019-05-14 2019-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 141 0 0.00 13 30.00 0.0001
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 141 141 10 0.0001
2018-05-16 2018-03-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 0 -14 -100.00 0 -100.00
2018-02-13 2017-12-31 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 14 11 366.67 2 0.0000
2017-11-08 2017-09-30 13F ALNYLAM PHARMACEUTICALS INC COM COM 02043Q107 3 3 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.